Bank of America
ZNTL icon

Bank of America’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bank of America’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41M Sell
1,114,650
-17,644
-2% -$70.4K ﹤0.01% 3504
2026
Q1 		$2.65M Sell
1,132,294
-234,960
-17% -$607K ﹤0.01% 3923
2025
Q4 		$1.85M Sell
1,367,254
-181,527
-12% -$264K ﹤0.01% 4126
2025
Q3 		$2.34M Buy
1,548,781
+835,466
+117% +$1.25M ﹤0.01% 4690
2025
Q2 		$827K Sell
713,315
-416,777
-37% -$550K ﹤0.01% 5414
2025
Q1 		$1.8M Buy
1,130,092
+914,093
+423% +$1.97M ﹤0.01% 4767
2024
Q4 		$654K Sell
215,999
-559,537
-72% -$1.83M ﹤0.01% 5342
2024
Q3 		$2.85M Buy
775,536
+267,303
+53% +$971K ﹤0.01% 4256
2024
Q2 		$2.08M Buy
508,233
+32,277
+7% +$360K ﹤0.01% 4418
2024
Q1 		$7.5M Sell
475,956
-242,687
-34% -$3.34M ﹤0.01% 3256
2023
Q4 		$10.9M Buy
718,643
+485,680
+208% +$7.09M ﹤0.01% 2798
2023
Q3 		$4.67M Sell
232,963
-32,521
-12% -$825K ﹤0.01% 3475
2023
Q2 		$7.49M Sell
265,484
-34,806
-12% -$835K ﹤0.01% 2998
2023
Q1 		$5.16M Buy
300,290
+59,950
+25% +$1.21M ﹤0.01% 3518
2022
Q4 		$4.84M Buy
240,340
+118,205
+97% +$2.54M ﹤0.01% 3415
2022
Q3 		$2.65M Sell
122,135
-187,332
-61% -$5.12M ﹤0.01% 4030
2022
Q2 		$8.7M Buy
309,467
+25,219
+9% +$668K ﹤0.01% 2832
2022
Q1 		$13.1M Buy
284,248
+86,859
+44% +$4.69M ﹤0.01% 2593
2021
Q4 		$16.6M Buy
197,389
+113,038
+134% +$8.75M ﹤0.01% 2404
2021
Q3 		$5.62M Buy
84,351
+2,524
+3% +$146K ﹤0.01% 3450
2021
Q2 		$4.35M Sell
81,827
-8,715
-10% -$467K ﹤0.01% 3647
2021
Q1 		$3.93M Buy
90,542
+42,478
+88% +$1.83M ﹤0.01% 3638
2020
Q4 		$2.5M Buy
48,064
+18,132
+61% +$818K ﹤0.01% 3751
2020
Q3 		$979K Buy
29,932
+12,993
+77% +$455K ﹤0.01% 4227
2020
Q2 		$814K Buy
+16,939
New +$650K ﹤0.01% 4265

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Bank of America's ZNTL Position: Q2 2026 in Review

Bank of America reduced its Zentalis Pharmaceuticals (ZNTL) stake by 1.6% in Q2 2026, selling an estimated $70.4K and leaving 1,114,650 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Bank of America first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $16.6M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Bank of America held 1,114,650 shares of Zentalis Pharmaceuticals worth $5.41M as of Q2 2026.
  • Bank of America sold 17,644 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $70.4K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3504 holding.
  • Bank of America first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Bank of America's Zentalis Pharmaceuticals position peaked at $16.6M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.